Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Hold” by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have been assigned a consensus rating of “Hold” from the fifteen research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.10.

A number of brokerages recently issued reports on IOVA. Barclays boosted their price target on Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Chardan Capital lowered their target price on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, November 6th. HC Wainwright cut their price target on Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, October 29th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Iovance Biotherapeutics in a report on Wednesday, October 8th.

Iovance Biotherapeutics Price Performance

Shares of IOVA opened at $2.45 on Monday. Iovance Biotherapeutics has a 1-year low of $1.64 and a 1-year high of $7.03. The company has a 50-day moving average of $2.42 and a 200 day moving average of $2.34. The firm has a market capitalization of $970.59 million, a price-to-earnings ratio of -2.04 and a beta of 0.77.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $67.46 million for the quarter, compared to the consensus estimate of $76.20 million. Iovance Biotherapeutics had a negative net margin of 158.78% and a negative return on equity of 55.24%. On average, equities analysts anticipate that Iovance Biotherapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Large investors have recently modified their holdings of the business. Vontobel Holding Ltd. bought a new position in shares of Iovance Biotherapeutics during the third quarter valued at approximately $26,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Iovance Biotherapeutics during the third quarter worth $27,000. Federated Hermes Inc. lifted its holdings in Iovance Biotherapeutics by 67.6% during the third quarter. Federated Hermes Inc. now owns 15,111 shares of the biotechnology company’s stock worth $33,000 after buying an additional 6,095 shares during the period. Wealthfront Advisers LLC bought a new stake in Iovance Biotherapeutics during the 3rd quarter valued at $34,000. Finally, R Squared Ltd increased its holdings in shares of Iovance Biotherapeutics by 41.4% in the 3rd quarter. R Squared Ltd now owns 16,043 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 4,700 shares during the period. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.